apomorphine has been researched along with xe 991, anthracenone in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Jia, L; Liu, H; Shi, L; Xie, J | 1 |
1 other study(ies) available for apomorphine and xe 991, anthracenone
| Article | Year |
|---|---|
The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Anthracenes; Apomorphine; Corpus Striatum; Dopamine; Dopamine Agonists; Dopaminergic Neurons; Infusions, Intraventricular; KCNQ Potassium Channels; Male; Motor Activity; Muscle Rigidity; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Potassium Channel Blockers; Rats, Wistar; Substantia Nigra | 2018 |